Loading
A phase 3 trial of Amivantamab, Cetuximab, Bevacizumab and Leucovorin (folinic acid) in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy is a phase 3 interventional study registered as NCT06750094 by Janssen Research & Development, LLC, with 700 participants planned, started 2024-12-12 and due to reach its primary completion in 2027-12-15. Interventions recorded: Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin and Irinotecan.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Amivantamab, Leucovorin (folinic acid), Johnson & Johnson, Cetuximab and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies, Colorectal cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/